Personalised pharmacometabolomic optimisation of treatment for hypertension (HYPERMARKER)

高血压，或称高血压（BP），是一种严重的疾病，也是导致循环系统疾病的最大因素，在整个欧盟，循环系统疾病仍是导致死亡和发病的主要原因。它几乎占所有医疗保健相关费用的10%。收缩期高血压导致各种各样的疾病，对患者和医疗保健系统都有巨大的影响。HYPERMARKER将释放药物代谢组学的潜力，为抗高血压治疗提供“智能”处方。来自11个欧洲国家的表型良好的队列将提供代谢组学概况和血液样本，用于药物代谢组学评估，以使用先进的人工智能和深度学习方法确定高血压治疗反应的预测因素。个体抗高血压药物治疗反应的预测模型将通过欧洲4个地点的创新随机对照试验进行临床验证和完善。结果是一个临床决策支持工具，使临床医生能够做出明智的选择，他们正在治疗的患者是否对使用血管紧张素抑制剂、钙拮抗剂、受体阻滞剂或一系列其他基于证据的现有药物有最好的反应。为确保可持续性，该项目还将制定一个框架，以便在欧洲及其他地区高血压患者的常规护理中采用这一工具。HYPERMARKER将由一组世界级的科学家和临床医生实施，这些科学家和临床医生来自不同的学科，他们曾多次合作，并在领导国家和欧盟资助的关键计划方面拥有良好的记录，以提供高影响力的结果。

Hypertension, or high blood pressure (BP), is a serious medical condition, and the single biggest contributor to circulatory diseases which continue to dominate as the leading cause of death and morbidity across the EU. It accounts for almost 10 percent of all healthcare-related costs. Systolic hypertension leads to a broad variety of diseases with an immense impact on both patients and healthcare systems. HYPERMARKER will unleash the potential of pharmacometabolomics to provide a ‘smart’ prescription of antihypertensive therapy. Well-phenotyped cohortsfrom eleven European countries will provide metabolomic profiles and blood samples for pharmacometabolomic assessments to identify predictors of treatment response in hypertension using advanced AI and deep learning methods. Prediction models for individual treatment responses to antihypertensive medication will be clinically validated and refined through an innovative RCT across 4 sites in Europe. The result is a clinical decision support tool that will give clinicians the ability to make an informed selection of whether the patient they are treating will best respond to the use of angiotensin inhibition, calcium antagonists, beta-blockers, or a range of other existing drugs with evidence-based for BP control. To ensure sustainability, the project will also develop a framework for the uptake of this tool in routine care for patients with hypertension across Europe and beyond. HYPERMARKER will be implemented by a group of world-class scientists and clinicians from a diversity of disciplines who have collaborated multiple times and have a track record of leading key national and EU-funded initiatives to deliver high-impact results.